Google Übersetzer
Wuxi Biologics
About
Wuxi Biologics (HK:2269) — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
Apr 24 2026
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
Apr 23 2026
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
Apr 17 2026
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
Apr 15 2026
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
Financials
Revenue
HK$21.79 B
Market Cap
HK$144.59 B
P/E Ratio
26.50
EPS
0.99